AclarionACON -3.59%31 Forward PE Ratio is 0.00 as of Jul. 12, 2026. GuruFocus rates ACON with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 314 Healthcare Providers & Services companies, Aclarion ranks worse than 318471.02% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Aclarion Forward PE Ratio Related Terms
Aclarion Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Aclarion's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclarion Forward PE Ratio Chart
Aclarion Annual Data
Trend
Forward PE Ratio
Aclarion Quarterly Data
Forward PE Ratio
ACON vs WLSS, VYND, MGRX: Forward PE Ratio Comparison
For the Health Information Services subindustry, Aclarion's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclarion Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Aclarion's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Aclarion's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Aclarion (ACON) has a Forward PE Ratio of 0.00 as of Jul. 12, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Aclarion and its competitors. According to the industry distribution chart, Aclarion ranks #999999 out of 314 companies in the Healthcare Providers & Services industry.
Is Aclarion's Forward PE Ratio too high?
Aclarion's current Forward PE Ratio is 0.00. Based on the distribution chart, Aclarion ranks #999999 out of 314 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Aclarion has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Aclarion's Forward PE Ratio compare to WLSS and VYND?
According to the Healthcare Providers & Services industry distribution chart, Aclarion ranks #999999 out of 314 companies for Forward PE Ratio. This places Aclarion in the lower half of its industry. The industry median Forward PE Ratio is 18.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.20, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Aclarion and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aclarion's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclarion stock overvalued right now?
Aclarion (ACON) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Aclarion's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Aclarion (ACON), the current Forward PE Ratio is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
31GF Score
Get the complete analysis for ACON
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACON has been successfully added to your 